QOL MEDICAL, LLC DISCONTINUES SPONSORSHIP OF THE ¹³C-SUCROSE BREATH TEST PROGRAM EFFECTIVE MARCH 1, 2025

VERO BEACH, Fla., Feb. 19, 2025 /PRNewswire/ — QOL Medical, LLC, a ground-breaking rare disease pharmaceutical company, has announced that it will no longer sponsor the ¹³C-sucrose breath test program, which was previously offered free of charge to patients presenting with symptoms of Congenital Sucrase-Isomaltase Deficiency (CSID). This change will take effect on March 1, 2025.

Congenital Sucrase-Isomaltase Deficiency (CSID) is largely a clinical diagnosis that requires a thorough review of the patient’s medical history. While there are several tests available to aid in diagnosing CSID, the breath test remains an important diagnostic tool.

Following this change, the ¹³C-sucrose breath test will still be available through Metabolic Solutions, but patients and/or their insurance will now be responsible for covering the cost of the test.

For any questions about the ¹³C-sucrose breath test, including details on reimbursement, patients and healthcare providers are encouraged to contact Metabolic Solutions directly.

Contact information for Metabolic Solutions:

• Phone: 603-598-6960
• Email: info@metsol.com 

QOL Medical remains committed to improving quality of life for patients and thanks everyone for their understanding of this transition.

About CSID

People with CSID, commonly known as sucrose (sugar) intolerance, are unable to properly digest sucrose (table sugar), which is found in foods like ice cream, apples, cake, and corn. In adolescents and adults, CSID has been characterized by symptoms of chronic abdominal pain, gas, bloating, and diarrhea, which overlap with common irritable bowel syndrome (IBS) symptoms. In infants, CSID classically presents as explosive watery diarrhea, failure to thrive, diaper rash, irritability, and acidic stools.

About QOL Medical, LLC

QOL Medical is a specialty biopharmaceutical company committed to delivering rare solutions for rare diseases—driven by you. Founded in 2003, QOL Medical focuses on improving clinical outcomes and enhancing the quality of life for patients with rare diseases through the acquisition and commercialization of orphan and gastrointestinal products in underserved markets. Learn more at www.qolmed.com.

Media Contact:

QOL Medical, LLC

Tiffany Carter

Phone: 818-720-8557

Email: tiffany@tlcmarketingpr.com

Corporate Contact:

QOL Medical, LLC

3405 Ocean Drive

Vero Beach, FL 32963

Phone: 866-469-3773

Fax: 772-365-3375

Email: info@qolmed.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/qol-medical-llc-discontinues-sponsorship-of-the-c-sucrose-breath-test-program-effective-march-1-2025-302379572.html

SOURCE QOL Medical, LLC

Disclaimer: The above press release comes to you under an arrangement with PR Newswire. We takes no editorial responsibility for the same.